This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.
Amgen announced positive top-line results from a Phase 3 trial evaluating Vectibix (panitumumab) in combination with FOLFIRI (an irinotecan-based chemotherapy) as a second-line treatment in 1,186 patients with metastatic colorectal cancer (mCRC). The co-primary endpoints, tested independently, were progression-free and overall survival.
We care about your feedback. Let us know how we can improve your CancerCompass experience.